Semaglutide

Lilly’s Zepbound had earlier outperformed Wegovy (20.2% compared with 13.7%) in a head-to-head weight-loss study. This could lead to a shift in patient preference from Wegovy to Zepbound, potentially resulting in a loss…

The drugs are effective and could potentially help a huge swath of the US population. But the drugs are expensive and many health plans don't cover them. Delp is hardly…